Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 7, 2023
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis (CRS) patients who have had prior ethmoid sinus surgery –
